(window.webpackJsonp=window.webpackJsonp||[]).push([[25],{350:function(t,s,v){"use strict";v.r(s);var _=v(4),r=Object(_.a)({},(function(){var t=this,s=t.$createElement,v=t._self._c||s;return v("ContentSlotsDistributor",{attrs:{"slot-key":t.$parent.slotKey}},[v("p",[t._v("题目: 人类自然杀伤细胞的泛癌单细胞全景图"),v("br"),t._v("\nDOI: "),v("a",{attrs:{href:"https://doi.org/10.1016/j.cell.2023.07.034",target:"_blank",rel:"noopener noreferrer"}},[t._v("https://doi.org/10.1016/j.cell.2023.07.034"),v("OutboundLink")],1),v("br"),t._v("\nCite:Fei Tang,Jinhu Li,Lu Qi et al.A pan-cancer single-cell panorama of human natural killer cells, Cell, 14 September 2023.")]),t._v(" "),v("p",[v("strong",[t._v("作者介绍：")])]),t._v(" "),v("table",[v("thead",[v("tr",[v("th",{staticStyle:{"text-align":"center"}},[t._v("Zemin Zhang")])])]),t._v(" "),v("tbody",[v("tr",[v("td",{staticStyle:{"text-align":"center"}},[v("img",{attrs:{src:"https://icg.pku.edu.cn/images/content/2019-01/20190111141522802087.png",width:"200"}})])]),t._v(" "),v("tr",[v("td",{staticStyle:{"text-align":"center"}},[t._v("北京大学")])]),t._v(" "),v("tr",[v("td",{staticStyle:{"text-align":"center"}},[v("a",{attrs:{href:"mailto:zemin@pku.edu.cn"}},[t._v("zemin@pku.edu.cn")])])])])]),t._v(" "),v("h2",{attrs:{id:"highlights"}},[v("a",{staticClass:"header-anchor",attrs:{href:"#highlights"}},[t._v("#")]),t._v(" Highlights:")]),t._v(" "),v("p",[t._v("• 人类 NK 细胞表现出肿瘤类型特异性亚组异质性"),v("br"),t._v("\n• RGS1表达是组织浸润 NK 细胞的可靠标志"),v("br"),t._v("\n• 肿瘤相关 NK 细胞的转录组特征表明细胞毒性受损"),v("br"),t._v("\n• 基于空间分析，LAMP3"),v("sup",[t._v("+")]),t._v(" DC 似乎可以调节肿瘤中的 NK 细胞功能")]),t._v(" "),v("h2",{attrs:{id:"summary"}},[v("a",{staticClass:"header-anchor",attrs:{href:"#summary"}},[t._v("#")]),t._v(" Summary:")]),t._v(" "),v("p",[t._v("自然杀伤（NK）细胞在对抗肿瘤进展的先天免疫反应中发挥着不可或缺的作用。为了描述它们在肿瘤微环境中的表型和功能多样性，我们对 716 名癌症患者的 NK 细胞进行了综合单细胞 RNA 测序分析，涵盖 24 种癌症类型。我们以肿瘤类型特异性的方式观察了 NK 细胞组成的异质性。值得注意的是，我们已经鉴定出一组肿瘤相关 NK 细胞，它们在肿瘤中富集，表现出抗肿瘤功能受损，并且与不良预后和免疫治疗耐药性相关。特定的骨髓细胞亚群，特别是 LAMP3"),v("sup",[t._v("+")]),t._v("树突状细胞似乎介导 NK 细胞抗肿瘤免疫的调节。我们的研究提供了对基于 NK 细胞的癌症免疫的见解，并强调了 NK 细胞亚群作为治疗靶点的潜在临床用途。")]),t._v(" "),v("h2",{attrs:{id:"graphical-abstract"}},[v("a",{staticClass:"header-anchor",attrs:{href:"#graphical-abstract"}},[t._v("#")]),t._v(" Graphical abstract:")]),t._v(" "),v("p",[v("img",{attrs:{src:"https://www.cell.com/cms/attachment/cc0d6647-7430-41ee-8bea-fe63f95f2d22/fx1.jpg",alt:"Graphical abstract"}})]),t._v(" "),v("h2",{attrs:{id:"results"}},[v("a",{staticClass:"header-anchor",attrs:{href:"#results"}},[t._v("#")]),t._v(" Results:")]),t._v(" "),v("h3",{attrs:{id:"figure-1-pan-cancer-single-cell-atlas-of-nk-cells-and-their-characteristics"}},[v("a",{staticClass:"header-anchor",attrs:{href:"#figure-1-pan-cancer-single-cell-atlas-of-nk-cells-and-their-characteristics"}},[t._v("#")]),t._v(" Figure 1: Pan-cancer single-cell atlas of NK cells and their characteristics.")]),t._v(" "),v("p",[v("img",{attrs:{src:"https://www.cell.com/cms/attachment/17bb25c8-da66-47dc-842f-5670b9dd2e08/gr1.jpg",alt:"Figure 1"}})]),t._v(" "),v("div",{staticClass:"custom-block note"},[v("p",{staticClass:"custom-block-title"},[t._v("Figure 1. NK细胞的泛癌单细胞图谱及其特征")]),t._v(" "),v("p",[v("strong",[t._v("(A)")]),t._v(" 泛癌 NK 细胞分析中涉及的癌症类型。"),v("br"),t._v(" "),v("strong",[t._v("(B)")]),t._v(" 不同癌症类型的患者数量。y 轴通过平方根变换进行缩放。"),v("br"),t._v(" "),v("strong",[t._v("(C,D)")]),t._v(" CD56"),v("sup",[t._v("bright")]),t._v("CD16"),v("sup",[t._v("lo")]),t._v("细胞 (C) 和 CD56"),v("sup",[t._v("dim")]),t._v("CD16"),v("sup",[t._v("hi")]),t._v("细胞 (D) 的均匀流形近似和投影 (UMAP) 可视化。"),v("br"),t._v(" "),v("strong",[t._v("(E,F)")]),t._v(" 跨组织的(E)CD56"),v("sup",[t._v("dim")]),t._v("CD16"),v("sup",[t._v("hi")]),t._v("和(F)CD56"),v("sup",[t._v("bright")]),t._v("CD16"),v("sup",[t._v("lo")]),t._v("NK细胞亚群的组合物。"),v("br"),t._v(" "),v("strong",[t._v("(G)")]),t._v(" NK细胞中功能基因的表达模式。")])]),t._v(" "),v("h3",{attrs:{id:"figure-2-heterogeneity-of-tumor-infiltrating-nk-cells-across-cancer-types"}},[v("a",{staticClass:"header-anchor",attrs:{href:"#figure-2-heterogeneity-of-tumor-infiltrating-nk-cells-across-cancer-types"}},[t._v("#")]),t._v(" Figure 2: Heterogeneity of tumor-infiltrating NK cells across cancer types.")]),t._v(" "),v("p",[v("img",{attrs:{src:"https://www.cell.com/cms/attachment/43da4db0-5cd9-4ff9-8a5c-d793d24f511e/gr2.jpg",alt:"Figure 2"}})]),t._v(" "),v("div",{staticClass:"custom-block note"},[v("p",{staticClass:"custom-block-title"},[t._v("Figure 2. 不同癌症类型肿瘤浸润NK细胞的异质性")]),t._v(" "),v("p",[v("strong",[t._v("(A)")]),t._v(" 多种癌症类型中CD56"),v("sup",[t._v("dim")]),t._v("CD16"),v("sup",[t._v("hi")]),t._v("和CD56"),v("sup",[t._v("bright")]),t._v("CD16"),v("sup",[t._v("lo")]),t._v("NK细胞的相对比率。"),v("br"),t._v(" "),v("strong",[t._v("(B,C)")]),t._v(" 分别比较肿瘤和邻近非肿瘤组织之间两个主要 NK 群体的比例除以 NK 细胞总数的箱线图。"),v("br"),t._v(" "),v("strong",[t._v("(D)")]),t._v(" 箱线图显示肿瘤中选定 NK 细胞亚群的频率。"),v("br"),t._v(" "),v("strong",[t._v("(E)")]),t._v(" 热图显示 NK 细胞亚群中抑制性和激活性受体的分数。")])]),t._v(" "),v("h3",{attrs:{id:"figure-3-identification-of-rgs1-as-a-key-tissue-infiltrating-marker-for-nk-cells"}},[v("a",{staticClass:"header-anchor",attrs:{href:"#figure-3-identification-of-rgs1-as-a-key-tissue-infiltrating-marker-for-nk-cells"}},[t._v("#")]),t._v(" Figure 3: Identification of RGS1 as a key tissue-infiltrating marker for NK cells.")]),t._v(" "),v("p",[v("img",{attrs:{src:"https://www.cell.com/cms/attachment/dd2d15de-84e6-4d8d-9997-502b4c1148ef/gr3.jpg",alt:"Figure 3"}})]),t._v(" "),v("div",{staticClass:"custom-block note"},[v("p",{staticClass:"custom-block-title"},[t._v("Figure 3. RGS1作为NK细胞关键组织浸润标记物的鉴定")]),t._v(" "),v("p",[v("strong",[t._v("(A,B)")]),t._v(" 热图显示血液和非血液组织之间(A)CD56"),v("sup",[t._v("bright")]),t._v("CD16"),v("sup",[t._v("lo")]),t._v("和 (B) CD56"),v("sup",[t._v("dim")]),t._v("CD16"),v("sup",[t._v("hi")]),t._v(" NK 细胞的差异表达基因。行代表特征基因，列代表不同的患者。"),v("br"),t._v(" "),v("strong",[t._v("(C,D)")]),t._v(" UMAP 图显示(C) CD56"),v("sup",[t._v("bright")]),t._v("CD16"),v("sup",[t._v("lo")]),t._v("和 (D) CD56"),v("sup",[t._v("dim")]),t._v("CD16"),v("sup",[t._v("hi")]),t._v(" NK 细胞中的RGS1表达及其组织分布。"),v("br"),t._v(" "),v("strong",[t._v("(E)")]),t._v(" 不同组织中 CD56"),v("sup",[t._v("bright")]),t._v("CD16"),v("sup",[t._v("lo")]),t._v("和CD56"),v("sup",[t._v("dim")]),t._v("CD16"),v("sup",[t._v("hi")]),t._v(" NK 细胞的组织驻留和迁移信号的表达模式。蓝线标记组织驻留信号，红线标记迁移信号。"),v("br"),t._v(" "),v("strong",[t._v("(F)")]),t._v(" CD69、ITGAE和RGS1及其组合在基于计算机荧光激活细胞分选 (FACS) 的区分组织源性 NK 细胞中的性能。红点表示源自血液的 NK 细胞，灰点表示源自组织的 NK 细胞。虚线表示根据表达水平预测的血液和非血液 NK 细胞的边界。"),v("br"),t._v(" "),v("strong",[t._v("(G)")]),t._v(" 小提琴图显示泛癌水平组织中RGS1 的表达。"),v("br"),t._v(" "),v("strong",[t._v("(H)")]),t._v(" 热图显示了所分析的癌症类型的血液、肿瘤和邻近非肿瘤组织中RGS1的平均表达。")])]),t._v(" "),v("h3",{attrs:{id:"figure-4-characteristics-of-tumor-associated-nk-cells"}},[v("a",{staticClass:"header-anchor",attrs:{href:"#figure-4-characteristics-of-tumor-associated-nk-cells"}},[t._v("#")]),t._v(" Figure 4: Characteristics of tumor-associated NK cells.")]),t._v(" "),v("p",[v("img",{attrs:{src:"https://www.cell.com/cms/attachment/778458c9-de04-44a9-b083-81fc5bd34955/gr4.jpg",alt:"Figure 4"}})]),t._v(" "),v("div",{staticClass:"custom-block note"},[v("p",{staticClass:"custom-block-title"},[t._v("Figure 4. 肿瘤相关NK细胞的特征")]),t._v(" "),v("p",[v("strong",[t._v("(A)")]),t._v(" 覆盖在 CD56"),v("sup",[t._v("dim")]),t._v("CD16"),v("sup",[t._v("hi")]),t._v(" NK 细胞UMAP 上的 RNA 速度。"),v("br"),t._v(" "),v("strong",[t._v("(B)")]),t._v(" 来自肿瘤和邻近非肿瘤组织的 CD56"),v("sup",[t._v("dim")]),t._v("CD16"),v("sup",[t._v("hi")]),t._v(" NK 细胞的密度图。虚线代表 c6-DNAJB1 细胞的富集区域。"),v("br"),t._v(" "),v("strong",[t._v("(C)")]),t._v(" 火山图显示肿瘤和邻近非肿瘤组织之间CD56"),v("sup",[t._v("dim")]),t._v("CD16"),v("sup",[t._v("hi")]),t._v(" NK 细胞的差异表达基因。"),v("br"),t._v(" "),v("strong",[t._v("(D)")]),t._v(" 通过多重免疫荧光染色显示 TaNK 细胞的 HCC 肿瘤的代表性示例（箭头）。"),v("br"),t._v(" "),v("strong",[t._v("(E)")]),t._v(" 使用流式细胞术检测肝癌患者的肿瘤和邻近非肿瘤区域中CD56"),v("sup",[t._v("dim")]),t._v("CD16"),v("sup",[t._v("hi")]),t._v(" HSP40"),v("sup",[t._v("+")]),t._v(" NK细胞在CD56"),v("sup",[t._v("dim")]),t._v("CD16"),v("sup",[t._v("hi")]),t._v(" NK细胞中的百分比。"),v("br"),t._v(" "),v("strong",[t._v("(F)")]),t._v(" 沿伪时间绘制的基因表达。"),v("br"),t._v(" "),v("strong",[t._v("(G)")]),t._v(" 箱线图显示 CD56"),v("sup",[t._v("dim")]),t._v("CD16"),v("sup",[t._v("hi")]),t._v(" c4−NFKBIA、c6-DNAJB1 和 c7-NR4A3 细胞之间的特征得分。"),v("br"),t._v(" "),v("strong",[t._v("(H)")]),t._v(" 通过多重免疫荧光染色的 HCC 肿瘤的代表性示例，显示 HSP40"),v("sup",[t._v("+")]),t._v("（白色箭头）和 HSP40"),v("sup",[t._v("−")]),t._v(" NK 细胞（红色箭头）中颗粒酶 B 的表达。"),v("br"),t._v(" "),v("strong",[t._v("(I,J)")]),t._v(" 使用流式细胞术比较肝癌患者肿瘤区域中(I) 细胞毒性颗粒和 (J) CD56"),v("sup",[t._v("dim")]),t._v("CD16"),v("sup",[t._v("hi")]),t._v(" HSP40"),v("sup",[t._v("+")]),t._v("和 HSP40"),v("sup",[t._v("−")]),t._v(" NK 细胞的抑制剂受体。")])]),t._v(" "),v("h3",{attrs:{id:"figure-5-the-relationship-between-tank-cells-and-clinical-outcomes"}},[v("a",{staticClass:"header-anchor",attrs:{href:"#figure-5-the-relationship-between-tank-cells-and-clinical-outcomes"}},[t._v("#")]),t._v(" Figure 5: The relationship between TaNK cells and clinical outcomes.")]),t._v(" "),v("p",[v("img",{attrs:{src:"https://www.cell.com/cms/attachment/c6a12afb-5e47-4e9b-a319-a560d8cbbcf3/gr5.jpg",alt:"Figure 5"}})]),t._v(" "),v("div",{staticClass:"custom-block note"},[v("p",{staticClass:"custom-block-title"},[t._v("Figure 5. TaNK细胞与临床结果的关系")]),t._v(" "),v("p",[v("strong",[t._v("(A)")]),t._v(" 肿瘤中特定 NK 细胞和 T 细胞亚群中选定基因的表达模式。"),v("br"),t._v(" "),v("strong",[t._v("(B)")]),t._v(" CD56"),v("sup",[t._v("dim")]),t._v("CD16"),v("sup",[t._v("hi")]),t._v(" c6-DNAJB1 NK 细胞在所有癌症类型的 NK 细胞中的比例。"),v("br"),t._v(" "),v("strong",[t._v("(C)")]),t._v(" 比较不同肿瘤阶段中 TaNK 细胞在所有 NK 细胞中的比例的箱线图。"),v("br"),t._v(" "),v("strong",[t._v("(D)")]),t._v(" 森林图显示 TaNK 细胞对总体存活率的影响。"),v("br"),t._v(" "),v("strong",[t._v("(E)")]),t._v(" Kaplan-Meier 图显示肿瘤中 TaNK 细胞的特征活性与预后的关联。"),v("br"),t._v(" "),v("strong",[t._v("(F)")]),t._v(" 比较ICB 治疗数据集中无应答者 (NR) 和应答者 (Rs) 之间CD56"),v("sup",[t._v("dim")]),t._v("CD16"),v("sup",[t._v("hi")]),t._v(" NK细胞中 TaNK 细胞比例的箱线图。"),v("br"),t._v(" "),v("strong",[t._v("(G)")]),t._v(" 箱线图显示，在批量 RNA-seq 数据集中，NR 表现出比 R 更高的 TaNK 细胞信号。")])]),t._v(" "),v("h3",{attrs:{id:"figure-6-the-relationship-of-lamp3-dcs-with-cd56dimcd16hi-nk-cells-across-cancer-types"}},[v("a",{staticClass:"header-anchor",attrs:{href:"#figure-6-the-relationship-of-lamp3-dcs-with-cd56dimcd16hi-nk-cells-across-cancer-types"}},[t._v("#")]),t._v(" Figure 6: The relationship of LAMP3+ DCs with CD56dimCD16hi NK cells across cancer types.")]),t._v(" "),v("p",[v("img",{attrs:{src:"https://www.cell.com/cms/attachment/844162dd-f088-40ab-abbd-7cabc5432ad1/gr6.jpg",alt:"Figure 6"}})]),t._v(" "),v("div",{staticClass:"custom-block note"},[v("p",{staticClass:"custom-block-title"},[t._v("Figure 6. 不同癌症类型中LAMP3"),v("sup",[t._v("+")]),t._v(" DC与 CD56"),v("sup",[t._v("dim")]),t._v("CD16"),v("sup",[t._v("hi")]),t._v(" NK细胞的关系")]),t._v(" "),v("p",[v("strong",[t._v("(A)")]),t._v(" 热图显示每个簇的重要配体-受体对的数量。"),v("br"),t._v(" "),v("strong",[t._v("(B)")]),t._v(" 气泡热图显示了肿瘤中 CD56"),v("sup",[t._v("dim")]),t._v("CD16"),v("sup",[t._v("hi")]),t._v(" NK 和其他免疫细胞簇相互作用的选定配体-受体对。"),v("br"),t._v(" "),v("strong",[t._v("(C-F)")]),t._v(" HCC 肿瘤中邻近和远离 ANXA1"),v("sup",[t._v("+")]),t._v(" NK 细胞的巨噬细胞上 (C 和 D) CD86 或 (E 和 F) TGF-β 表达的代表性图像和荧光强度定量。"),v("br"),t._v(" "),v("strong",[t._v("(G)")]),t._v(" 基于 scRNA-seq 数据的主要免疫群体中IL15、PVR和PVRL2的表达模式。"),v("br"),t._v(" "),v("strong",[t._v("(H)")]),t._v(" 通过流式细胞术分析 HCC 患者肿瘤组织中 IL-15 表达的代表性图。"),v("br"),t._v(" "),v("strong",[t._v("(I)")]),t._v(" 散点图显示TCGA 数据集中 CD56"),v("sup",[t._v("dim")]),t._v("CD16"),v("sup",[t._v("hi")]),t._v(" NK 细胞与 LAMP3"),v("sup",[t._v("+")]),t._v(" DC 的相关性"),v("br"),t._v(" "),v("strong",[t._v("(J)")]),t._v(" 多重免疫荧光染色显示 LAMP3"),v("sup",[t._v("+")]),t._v(" DC (DC-LAMP3"),v("sup",[t._v("+")]),t._v(" ) 和 NK 细胞 (CD3"),v("sup",[t._v("−")]),t._v(" CD56"),v("sup",[t._v("+")]),t._v(" )的共定位。"),v("br"),t._v(" "),v("strong",[t._v("(K)")]),t._v(" 使用 Halo v3.3 图像分析平台 (Indica) 对 (D) 中靠近 LAMP3"),v("sup",[t._v("+")]),t._v(" DC (n = 19) 或远离 LAMP3"),v("sup",[t._v("+")]),t._v(" DC (n = 26) 的 NK 细胞中颗粒酶 B 的荧光强度进行定量实验）。")])]),t._v(" "),v("h2",{attrs:{id:"discussion"}},[v("a",{staticClass:"header-anchor",attrs:{href:"#discussion"}},[t._v("#")]),t._v(" Discussion:")]),t._v(" "),v("h3",{attrs:{id:"figure-7-summary-of-nk-cell-features-and-dynamics-in-this-study"}},[v("a",{staticClass:"header-anchor",attrs:{href:"#figure-7-summary-of-nk-cell-features-and-dynamics-in-this-study"}},[t._v("#")]),t._v(" Figure 7: Summary of NK cell features and dynamics in this study.")]),t._v(" "),v("p",[v("img",{attrs:{src:"https://www.cell.com/cms/attachment/b9ce1e10-6666-4008-974c-c2210cf5f02e/gr7.jpg",alt:"Figure 7"}})]),t._v(" "),v("div",{staticClass:"custom-block note"},[v("p",{staticClass:"custom-block-title"},[t._v("Figure 7. 本研究中NK细胞特征和动态总结")]),t._v(" "),v("p",[v("strong",[t._v("(A)")]),t._v(" CD56"),v("sup",[t._v("bright")]),t._v("CD16"),v("sup",[t._v("lo")]),t._v(" c5-CREM NK 细胞下调肿瘤中的XCL2和XCL1，可能导致 cDC1 募集减弱。"),v("br"),t._v(" "),v("strong",[t._v("(B)")]),t._v(" CD56"),v("sup",[t._v("bright")]),t._v("CD16"),v("sup",[t._v("lo")]),t._v(" c3-CCL3 NK 细胞在肿瘤（包括CCL3和CCL4）中表现出细胞因子产生减少。"),v("br"),t._v(" "),v("strong",[t._v("(C)")]),t._v(" 与循环 NK 细胞相反，肿瘤浸润 NK 细胞始终表达RGS1。"),v("br"),t._v(" "),v("strong",[t._v("(D)")]),t._v(" c6-DNAJB1 NK 细胞表现出较高的 KIR 表达、升高的应激反应和降低的细胞毒性，被认为是肿瘤浸润性 CD56"),v("sup",[t._v("dim")]),t._v("CD16"),v("sup",[t._v("hi")]),t._v(" NK 细胞的潜在功能障碍状态。"),v("br"),t._v(" "),v("strong",[t._v("(E)")]),t._v(" 细胞与 LAMP3"),v("sup",[t._v("+")]),t._v(" DC 的相互作用塑造肿瘤浸润 CD56"),v("sup",[t._v("dim")]),t._v("CD16"),v("sup",[t._v("hi")]),t._v(" NK 细胞功能。")])])])}),[],!1,null,null,null);s.default=r.exports}}]);